Guardant Health Announces Pricing of Upsized Public Offering of Common Stock - May 23, 2023
BIOMARKER
1. Guardant Health announces pricing of an upsized public offering of common stock at $28.00 per share.
2. The offering consists of 12,500,000 shares of common stock, with a 30-day option for underwriters to purchase an additional 1,875,000 shares.
3. The gross proceeds from the offering are expected to be $350.0 million.
4. The offering is scheduled to close on May 25, 2023, pending customary closing conditions.
5. J.P. Morgan, Goldman Sachs & Co. LLC, TD Cowen, and SVB Securities are acting as joint book-running managers for the offering.
6. The shares are being offered under an automatic shelf registration statement on Form S-3.
7. Copies of the preliminary prospectus supplement and accompanying prospectus can be obtained from the designated contacts.
8. The press release emphasizes that this is not an offer to sell or solicitation to buy securities.
9. Guardant Health is a precision oncology company focused on advancing cancer care through its tests, data sets, and analytics.
10. Forward-looking statements caution investors about known and unknown risks and uncertainties associated with the public offering and Guardant Health's business.